Information  X 
Enter a valid email address

Oxford BioDynamics (OBD)

  Print      Mail a friend

Tuesday 01 May, 2018

Oxford BioDynamics

Total Voting Rights

RNS Number : 6302M
Oxford BioDynamics PLC
01 May 2018
 

1 May 2018

 

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

TOTAL VOTING RIGHTS

 

Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture for use within the pharmaceutical and biotechnology industry, announces that in conformity with the FCA's Disclosure Guidance and Transparency Rule 5.6.1, the Company notifies the market that as at 30 April 2018, the Company's total issued share capital consists of 87,483,306 ordinary shares with one voting right per share. The Company does not hold any ordinary shares in Treasury. Therefore, the total number of voting rights in the Company is 87,483,306.

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

For further details, contact:

 

Oxford BioDynamics Plc


+44 (0)1865 518910

Christian Hoyer Millar, CEO



Paul Stockdale, CFO






Shore Capital


+44 (0)20 7408 4090

Nominated Advisor and Broker



Stephane Auton

Edward Mansfield






FTI Consulting  


+44 (0)20 3727 1000

Financial Public Relations Advisor



Brett Pollard



Natalie Garland-Collins



 

Notes for Editors

 

About Oxford BioDynamics Plc

 

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. 

 

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. 

 

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery.  Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

 

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD".  For more information please visit www.oxfordbiodynamics.com.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVRFMGFDKGMGRZM

a d v e r t i s e m e n t